Skip to contentY
Yubo International Biotech Ltd
Y
YBGJYubo International Biotech Ltd Q2 2023 · 10-Q
Revenue$1.43K$1.43K−82.1% vs Q2 2022 Net Income-$367.33K-$367.33KN/M vs Q2 2022 EPS, diluted—
Operating Income-$367,276N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Yubo International Biotech Ltd · CIK 895464 · Engraved from SEC EDGAR
Operating Cash Flowderived-$152,925N/M Free Cash Flowderived-$152,925N/M Margins · derivedGross margin61.9%−11.5 pt vs Q2 2022
Operating margin-25683.6%−19516.8 pt vs Q2 2022
Net margin-25687.2%−19519.6 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 11, 2023 · 42 d after period end